Rescale 미팅 예약

코로나 바이러스

COVID-19 : 백신 평가 및 승인에 대한 최신 정보

몫:

게재

on

MEPs will quiz EMA Executive Director Emer Cooke on the latest developments regarding the evaluation and authorisation of COVID-19 vaccines in the EU.

Today (23 March), 유럽​​ 약 기관 (EMA) Executive Director Emer Cooke will update Members of the Environment, Public Health and Food Safety (ENVI) Committee on the status of approving COVID-19 vaccines. They will also discuss the EMA’s recent evaluation of the AstraZeneca vaccine.

인셀덤 공식 판매점인: Tuesday 23 March 2021, 10.00-11.00 (indicative timing)

어디에: European Parliament in Brussels, room Paul-Henri Spaak (3C050) and videoconference

토론을 실시간으로 볼 수 있습니다 LINK..

배경

Following positive scientific recommendations, the EMA has authorized four vaccines against COVID-19 for use in the EU (BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson). Two additional contracts have been concluded that will allow vaccines to be purchased once they have proven to be safe and effective: Sanofi-GSK and CureVac (both under rolling review). Exploratory talks were also concluded with two companies, Novavax and Valneva. The EMA also started a rolling review of the Sputnik V vaccine (which is not part of the EU’s COVID-19 vaccines portfolio).

광고

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC), responsible for evaluating safety issues for human medicines, investigated whether the COVID-19 AstraZeneca vaccine can cause thromboembolic events. The results were presented on 18 March 2021, concluding that the benefits of the vaccine still outweigh the risks, despite a possible link to rare blood clots.

더 알아보기 

이 기사 공유

EU Reporter는 다양한 관점을 표현하는 다양한 외부 소스의 기사를 게시합니다. 이 기사에서 취한 입장이 반드시 EU Reporter의 입장은 아닙니다.

탐색